Moderna’s ambition to go beyond its COVID-19 vaccine success is gaining traction. It announced a positive Phase III readout for its mRNA-based flu shot candidate at its latest R&D day, and also revealed expanded plans for its potential first-in-class cancer immunotherapy, mRNA-4157.
Moderna has remained confident that its mRNA platform can deliver a whole new wave of growth from a broad range of programs in infectious diseases, rare disease and cancer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?